Medical Condition News

RSS

Study demonstrates rufinamide therapy is effective in reducing partial seizure frequency

Researchers from the Arkansas Epilepsy Program found treatment with rufinamide results in a significant reduction in seizure frequency compared with placebo, for patients with uncontrolled partial-onset seizures (POS).

1 Oct 2010

Study indicates neurotransmitters are abnormal in people with psychotic illness

There is growing evidence that two neurotransmitters - dopamine and glutamate - are abnormal in people with psychotic illness, including schizophrenia. Among many other things, these chemicals play a role in cognitive functions, such as memory, learning, and problem-solving.

1 Oct 2010

Mammography screening of middle-aged women reduces breast cancer mortality rate by 30%

The landmark breast cancer screening study of women 40-49, published online in Cancer, has proven that annual mammography screening of women in their 40s reduces the breast cancer death rate in these women by nearly 30 percent.

1 Oct 2010

Neurologic Clinics journal publishes latest advances in neurologic disorders

The latest advances in treating neurologic disorders such as stroke, headache, Parkinson's disease, epilepsy and sleep disorders are detailed in a special issue of the journal Neurologic Clinics.

1 Oct 2010

Wenzel Spine receives FDA marketing clearance for VariLift Expandable Interbody Fusion System

Wenzel Spine, Inc., a medical device company focused on offering less invasive, stand-alone alternatives to traditional spinal fusion, today announced they have received 510K clearance to market the VariLift Expandable Interbody Fusion System.

30 Sep 2010

Defibtech extends availability of Lifeline View Automatic External Defibrillator into Europe

Defibtech, LLC, a leading innovator in the Automated External Defibrillator (AED) market, today announced its first international shipment of the Lifeline View™ Automatic External Defibrillator to Medizon, one of Defibtech's largest international distributors and the exclusive distributor for the Netherlands. This shipment of the Lifeline View AED adds to the more than 100,000 Defibtech AEDs shipped worldwide.

30 Sep 2010

St. Jude Medical receives Japanese approval for Eon Mini spinal cord stimulation system

St. Jude Medical, Inc., a global medical device company, today announced regulatory approval from the Japanese Ministry of Health, Labor and Welfare (MHLW) of the Eon Mini™ spinal cord stimulation (SCS) system. The world's smallest, longest-lasting rechargeable neurostimulator, the Eon Mini device is the first rechargeable spinal cord stimulator to be approved for use in Japan.

30 Sep 2010

Avila commences AVL-292 Phase 1 clinical study for B cell cancers and autoimmune diseases

Avila Therapeutics™, Inc., a biotechnology company developing targeted covalent drugs, announced today that it has initiated a phase 1 clinical trial to assess the safety, tolerability and pharmacokinetic profile of AVL-292, a novel, orally available, covalent drug that targets Bruton's tyrosine kinase (Btk). AVL-292 is the first product candidate to enter clinical evaluation from Avila's proprietary covalent drug platform, Avilomics™.

30 Sep 2010

Consumption of caffeinated coffee and alcohol reduces risk of contracting late onset diabetes

In a very large cohort of African-American women in the US, the association between the consumption of alcohol, tea, and coffee and the development of type 2 diabetes mellitus (late onset diabetes) was studied for 12 years. Tea and decaffeinated coffee showed no relation with diabetes, but the regular moderate intake of both caffeinated coffee and alcohol appeared to reduce the risk of contracting late onset diabetes significantly.

30 Sep 2010

International scientists meet to progress cancer research

THE deliberations of a small group of specialists, meeting in Edinburgh tomorrow, will help make progress in cancer research all over the world.On Thursday (September 30) nineteen international scientists are due to get round the table to decide which cancer research projects, from the 125 in front of them, will benefit from a grants package totalling more than £4 million.

30 Sep 2010

Natural remedy for eczema

Eczema Free Forever provides answers with practical, homemade and natural solutions, that the eczema suffering population in any part of the world can easily perform in the comfort of their home.

30 Sep 2010

Agilent introduces SureSelect Kinome Target Enrichment Kit to focus next-generation sequencing studies

Agilent Technologies Inc. today introduced the SureSelect Kinome Target Enrichment Kit, enabling researchers to focus next generation sequencing studies on expressed kinases (the kinome). Researchers increasingly are looking at human kinases as a rich, proven source of biomarkers as well as potential drug targets for cancers and other diseases.

30 Sep 2010

Concentric Medical commences TREVO Study of Stentriever technology in ischemic stroke patients

Concentric Medical, Inc., the global leader in acute ischemic stroke intervention, today announced the start of the TREVO Study. The first patients were enrolled and successfully treated at the Hospital Clinic de Barcelona by the Neuroradiology team of Drs. Juan Macho and Jordi Blasco.

30 Sep 2010

Repligen Corporation completes patient enrollment in RG2417 Phase 2b clinical trial

Repligen Corporation reported today that it has completed enrollment of patients in its Phase 2b clinical trial of RG2417, an oral formulation of uridine, in patients with bipolar depression.

30 Sep 2010

sanofi-aventis announces top-line results from lixisenatide Phase III GETGOAL-L-ASIA trial for Type-2 Diabetes

Zealand Pharma A/S, the biopharmaceutical company dedicated to the discovery and development of innovative peptide-based drugs, is pleased to note that its partner, sanofi-aventis, has today announced positive top-line results of the Phase III GETGOAL-L-ASIA trial which assessed the efficacy and safety of lixisenatide, a once-daily GLP-1 receptor agonist discovered by Zealand Pharma, in combination with basal insulin.

30 Sep 2010

New approach to prevent psychotic symptoms

New research has linked psychosis with an abnormal relationship between two signalling chemicals in the brain. The findings, published in tomorrow's edition of the journal Biological Psychiatry, suggest a new approach to preventing psychotic symptoms, which could lead to better drugs for schizophrenia.

30 Sep 2010

Universitat Jaume I evaluates ruthenium compounds for neurodegenerative disease treatment

The pharmaceutical division of the company Neuron BPh and the research group of Organometallic Chemistry and Homogeneous Catalysis of the Universitat Jaume I, have evaluated the possible applications of a series of ruthenium compounds for their future use in the treatment of neurodegenerative disease such as Alzheimer.

30 Sep 2010

Teva Pharmaceuticals, OncoGenex initiate SYNERGY Phase 3 trial to evaluate custirsen

Teva Pharmaceuticals Industries Ltd. and OncoGenex Pharmaceuticals, Inc. announced today the initiation of SYNERGY, a global Phase 3 trial evaluating custirsen (also known as OGX-011/TV-1011) as first line therapy for the treatment of castrate-resistant prostate cancer (CRPC).

30 Sep 2010

AVEO regains global rights for development, commercialization of AV-299 anti-HGF antibody candidate

AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that AVEO has regained worldwide rights from Merck (through its subsidiary, Schering Corporation) to develop and commercialize AV-299 (also known as SCH 900105), its anti-hepatocyte growth factor (HGF) antibody candidate.

30 Sep 2010

FDA grants Type B meeting to review Phase III pivotal efficacy protocols for Androxal

Repros Therapeutics Inc. today announced that the Company has been granted a Type B meeting to be held on November 8, 2010 with the Division of Reproductive and Urologic Products to review the Company's Phase III pivotal efficacy protocols for Androxal in the treatment of secondary hypogonadism. Androxal is an oral drug that normalizes both testosterone and sperm levels.

30 Sep 2010

Medical Condition News

Study demonstrates rufinamide therapy is effective in reducing partial seizure frequency

Study indicates neurotransmitters are abnormal in people with psychotic illness

Mammography screening of middle-aged women reduces breast cancer mortality rate by 30%

Neurologic Clinics journal publishes latest advances in neurologic disorders

Wenzel Spine receives FDA marketing clearance for VariLift Expandable Interbody Fusion System

Defibtech extends availability of Lifeline View Automatic External Defibrillator into Europe

St. Jude Medical receives Japanese approval for Eon Mini spinal cord stimulation system

Avila commences AVL-292 Phase 1 clinical study for B cell cancers and autoimmune diseases

Consumption of caffeinated coffee and alcohol reduces risk of contracting late onset diabetes

International scientists meet to progress cancer research

Natural remedy for eczema

Agilent introduces SureSelect Kinome Target Enrichment Kit to focus next-generation sequencing studies

Concentric Medical commences TREVO Study of Stentriever technology in ischemic stroke patients

Repligen Corporation completes patient enrollment in RG2417 Phase 2b clinical trial

sanofi-aventis announces top-line results from lixisenatide Phase III GETGOAL-L-ASIA trial for Type-2 Diabetes

New approach to prevent psychotic symptoms

Universitat Jaume I evaluates ruthenium compounds for neurodegenerative disease treatment

Teva Pharmaceuticals, OncoGenex initiate SYNERGY Phase 3 trial to evaluate custirsen

AVEO regains global rights for development, commercialization of AV-299 anti-HGF antibody candidate

FDA grants Type B meeting to review Phase III pivotal efficacy protocols for Androxal

Transforming Cardiovascular Care: Insights from Mina Makar at AstraZeneca

Clue's CEO Rhiannon White on the Future of Femtech and PCOS

Freezing Point Osmometry in Life Science Applications

Latest News